Results 101 to 110 of about 13,871 (164)

Combination of metronomic oral pazopanib and topotecan for recurrent glioblastoma with and without previous bevacizumab: Results from a phase 2 clinical trial. [PDF]

Neurooncol Adv
Ozer BH, Cohen AL, Colman H, Penas-Prado M, de Groot J, Loghin ME, Pan E, Raizer JJ, Kumthekar P, Fink KL, Walbert T, Merrell RT, Groves MD, Ahluwalia MS, Wu J, Burton EC, Vera E, Mendoza T, Grajkowska E, Wall K, Reyes J, Yuan Y, Armstrong TS, Gilbert MR.   +23 more
europepmc   +1 more source

Cost-Effectiveness of Tarlatamab in the Second-Line Treatment of Refractory Small Cell Lung Cancer From a US Perspective. [PDF]

Clin Med Insights Oncol
Zheng H, Wen F, Wu B.
europepmc   +1 more source

Retinal organoid screening reveals ABT-737 and luminespib as potential agents against a cone- precursor-derived subtype of retinoblastoma. [PDF]

Mol Ther Oncol
Kelk J, Rozanska A, Sotiriadou E, Astley D, Hussain R, Unsworth A, Gangar A, Robinson A, Queen R, Coxhead J, Steel DH, Armstrong L, Parulekar M, Hardcastle I, Veal GJ, Lako M.   +15 more
europepmc   +1 more source

SGSS05-NS3, a covalent SETD8 inhibitor that activates p53 pathway in neuroblastoma. [PDF]

J Exp Clin Cancer Res
Liu Z, Bagchi S, Yan C, Hu Y, Blum G, Ma A, Jin J, Luo M, Di Bella S, Verona F, Appella E, Giannini G, Thiele CJ, Veschi V.   +13 more
europepmc   +1 more source

Multiscale analysis and optimal glioma therapeutic candidate discovery using the CANDO platform. [PDF]

J Cheminform
Xu S, Hu Y, Mangione W, Van Norden M, Elefteriou K, Falls Z, Samudrala R.   +6 more
europepmc   +1 more source

Integrated computational screening of FDA-approved anticancer drugs as novel HPV-16 E6 inhibitors in cervical cancer. [PDF]

Sci Rep
Ahmadi M, Yoosefian M.
europepmc   +1 more source

Targeted CRISPR knockout screening identifies known and novel chemogenomic interactions between DNA damaging agents and DNA repair genes. [PDF]

NAR Cancer
Heer CD, Elia JL, Menon V, Johnson SS, Arbelaez SR, Friedman S, Lopez-Giraldez F, Sundaram RK, Herzon SB, Bindra RS, Gueble SE.   +10 more
europepmc   +1 more source

Transcriptomic Analysis of TDP1-Knockout HEK293A Cells Treated with the TDP1 Inhibitor (Usnic Acid Derivative). [PDF]

Int J Mol Sci
Zakharenko AL, Dyrkheeva NS, Markov AV, Kleshchev MA, Ryabchikova EI, Malakhova AA, Orishchenko KE, Okorokova LS, Shtokalo DN, Medvedev SP, Zakian SM, Tupikin AA, Kabilov MR, Luzina OA, Deyev SM, Lavrik OI.   +15 more
europepmc   +1 more source

Treatment Patterns, Outcome, and Quality of Life of Patients With Extensive-Stage SCLC Receiving Third-Line Therapy-Data From the German CRISP Registry (AIO-TRK-0315): A Brief Report. [PDF]

JTO Clin Res Rep
Rost M, Fischer R, Reck M, Gauler T, Waller C, Christopoulos P, Hoffknecht P, Jänicke M, Fleitz A, Härzschel A, Lennartz C, Ludwig P, Groth A, Bendel M, Stratmann J, Griesinger F, Thomas M, Eberhardt WEE, Sebastian M.   +18 more
europepmc   +1 more source

Suvemcitug plus chemotherapy in women with platinum-resistant recurrent ovarian cancer: the SCORES randomized, double-blinded, phase 3 trial. [PDF]

Nat Cancer
Yuan G, Lou G, Li J, Xu M, Liu X, Wang D, Zhang K, Zhu T, Li X, Huang Y, Duan W, Wang K, Zhou Q, Li G, Yang C, Zhang J, Sun H, Tang R, Li Q, Wu L.   +19 more
europepmc   +1 more source